Glassman Wealth Services’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-289
| Closed | -$53K | – | 1916 |
|
|
2021
Q2 | $53K | Buy |
289
+22
| +8% | +$3.78K | 0.01% | 340 |
|
|
2021
Q1 | $41K | Buy |
267
+11
| +4% | +$1.7K | 0.01% | 365 |
|
|
2020
Q4 | $40K | Buy |
256
+29
| +13% | +$3.73K | 0.01% | 374 |
|
|
2020
Q3 | $26K | Buy |
227
+98
| +76% | +$10.6K | 0.01% | 401 |
|
|
2020
Q2 | $14K | Buy |
129
+85
| +193% | +$9.02K | ﹤0.01% | 442 |
|
|
2020
Q1 | $4K | Buy |
44
+31
| +238% | +$3.04K | ﹤0.01% | 579 |
|
|
2019
Q4 | $1K | Buy |
13
+9
| +225% | +$963 | ﹤0.01% | 1117 |
|
|
2019
Q3 | $0 | Sell |
4
-5
| -56% | -$564 | ﹤0.01% | 1504 |
|
|
2019
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 999 |
|
|
2019
Q1 | $1K | Sell |
9
-3
| -25% | -$373 | ﹤0.01% | 966 |
|
|
2018
Q4 | $1K | Hold |
12
| – | – | ﹤0.01% | 726 |
|
|
2018
Q3 | $2K | Hold |
12
| – | – | ﹤0.01% | 630 |
|
|
2018
Q2 | $1K | Buy |
12
+8
| +200% | +$935 | ﹤0.01% | 761 |
|
|
2018
Q1 | $0 | Sell |
4
-3
| -43% | -$359 | ﹤0.01% | 982 |
|
|
2017
Q4 | $1K | Sell |
7
-13
| -65% | -$1.58K | ﹤0.01% | 636 |
|
|
2017
Q3 | $3K | Hold |
20
| – | – | ﹤0.01% | 405 |
|
|
2017
Q2 | $2K | Sell |
20
-21
| -51% | -$2.44K | ﹤0.01% | 435 |
|
|
2017
Q1 | $5K | Buy |
41
+29
| +242% | +$3.74K | ﹤0.01% | 406 |
|
|
2016
Q4 | $1K | Buy |
12
+9
| +300% | +$1.1K | ﹤0.01% | 592 |
|
|
2016
Q3 | $0 | Buy |
+3
| New | +$386 | ﹤0.01% | 615 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM